Author Archive for: TG

Zurich-based oncology biotech Araris Biotech AG has entered into a research collaboration with an option to license with Japan’s Chugai Pharmaceutical, a subsidiary of Roche. The aim of the partnership is to develop next-generation antibody–drug conjugates (ADCs). While Araris itself is now Japanese-owned – a wholly owned subsidiary of Taiho Pharmaceutical, part of the Otsuka Group – its research activities remain firmly rooted in Zurich. That presence was highlighted last year when the Strüngmann brothers, German billionaire twins, awarded a prize to the company’s founders.

The Australian–Swiss plasma specialist CSL is relying on technology from Switzerland for recombinant polyclonal immunoglobulins (IgG). With Memo Therapeutics, the company has entered into a collaboration and option agreement with a total potential value of up to CHF 265 million. This is good news for Memo, while CSL, following substantial job cuts including in Marburg, could also use some different headlines for a change.

Bayer can report a success in stroke treatment, even though an earlier study with the same compound had been discontinued due to limited benefit. The approach of inhibiting factor XIa represents a first-in-class example from Leverkusen. Whether the data will be sufficient for regulatory approval remains to be seen.

Two of the U.K.’s largest life sciences real-estate projects have moved forward within days of each other, with major expansion plans unveiled in London and Cambridge as both regions look to add new laboratory and research capacity.

Just three weeks after announcing its plans for a U.S. listing, Belgium-based Agomab has gone public on Nasdaq after pricing its IPO at $16 per share, aiming to bring in about $200 million in gross proceeds with its stock now trading under the ticker AGMB.